John H. Krystal, USA
Dr. Krystal is the Robert L. McNeil, Jr., Professor of Translational Research, Chair of the Department of Psychiatry, and Professor of Neurobiology at the Yale University School of Medicine and Chief of Psychiatry at Yale-New Haven Hospital. He is a graduate of the University of Chicago, Yale University School of Medicine, and the Yale Psychiatry Residency Training Program. He has published over 400 papers and reviews on the neurobiology and treatment of schizophrenia, alcoholism, post-traumatic stress disorder, and depression. His research program unites psychopharmacology, neuroimaging, and molecular genetics. His work on brain glutamate systems contributed to the identification of novel treatment mechanisms for depression, alcoholism, and schizophrenia that are now in development. He is the Director of the NIAAA Center for the Translational Neuroscience of Alcoholism and the Clinical Neuroscience Division of the VA National Center for PTSD. Dr. Krystal received a number of awards including the Joel Elkes Award of the American College of Neuropsychopharmacology, the Anna-Monika Foundation Prize for Depression Research, and the NIAAA Jack Mendelson Alcoholism Research Award. He is also a member of the Institute of Medicine of the U.S. National Academy of Sciences. He was Chairman of the NIMH Board of Scientific Counselors (2004-2007), served on the NIAAA National Alcohol Advisory Council (2008-2012), and president of the American College of Neuropsychopharmacology (2012). Since 2006, he edited a leading psychiatry and neuroscience journal, Biological Psychiatry (IF=9.25).
Shigeto Yamawaki, Japan
Dr. Shigeto Yamawaki is Professor and Chairman of Psychiatry and Neurosciences, Hiroshima University, Japan. He has served as Councilor (2000-2004) and Secretary (2004-2006) of the CINP, and several committee members as well as an editorial board of the IJNP. He successfully organized the CINP Asia-Pacific regional meeting in Hiroshima, 2001. He has also served as President (2006-2008) of the International College of Geriatric Psychoneuropharmacology (ICGP), and as a founding President (2008-2010) of the Asian College of Neuropsychopharmacology (AsCNP). The major focus of his research is on the neurobiology and clinical psychopharmacology of mood disorders.His recent interest includes the molecular basis of early adverse life events on vulnerability for major depression, and the neuroimaging study on mood regulation using a visual emotion task and a future reward prediction task. He published more than 300 papers in the high impact international journals such as Nature Neuroscience, Biological Psychiatry, Journal of Neuroscience as well as IJNP.
Pierre Blier, Canada
Dr. Blier is a Full Professor of the Departments of Psychiatry and Cellular & Molecular Medicine, at the University of Ottawa, and Director of the Mood Disorders Research Program at the University of Ottawa Institute of Mental Health Research, Royal Ottawa Mental Health Care Center.
Dr. Blier is on the editorial boards of nine journals, the field editor for Translational Medicine for International Journal of Neuropsychopharmacology, and the Editor for the Americas of the Journal of Psychopharmacology. Has published over 450 abstracts and 270 peer-reviewed articles (h factor of 73) and has given lectures worldwide. He has a basic research laboratory investigating mechanisms of action of psychotropic medications, carries out investigator-initiated clinical studies, and treats patients with mood and anxiety disorders on a daily basis.
Dr. Blier has received several awards including the Canada Research Chair in Psychopharmacology (2004-2018) from the Government of Canada and the biennial CINP Basic Research Award in 2010.
Prof. Toshikazu Saito, Japan
I am a professor emeritus of Sapporo Medical University and a director of Psychiatry Institute of Hokujinkai Medical Corporation. I graduated from Sapporo Medical University, School of Medicine in 1973 and completed my psychiatry residency at Ishibashi Hospital two years later. I then entered the graduate school of medicine at Sapporo Medical University in 1975. In graduate school, I studied pharmacology for four years and received a PhD degree from the university in 1979. I became an associate professor in 1991. During this time, I spent several years in the Department of Physiology & Biophysics, University of Illinois at Chicago studying alterations in signal transduction in the model rat of alcoholism under the supervision of Dr. Boris Tabakoff. I became a professor and chairman of the Department of Neuropsychiatry in the School of Medicine at Sapporo Medical University in 1998. I became a councilor of CINP in 2010.
Prof. Siegfried Kasper, Austria
Dr. Siegfried Kasper is Professor of Psychiatry and Chairman of the Department of Psychiatry and Psychotherapy at the Medical University of Vienna, Austria. Born in Salzburg, Austria, he was educated at the medical schools of the University of Innsbruck, Austria and the Universities of Freiburg and Heidelberg, Germany. Dr. Kasper gained clinical and research experience in psychiatry at the Central Institute of Mental Health, Mannheim, Germany, the Psychiatric Department of the University of Heidelberg, Germany, the Clinical Psychobiology Branch of the National Institute of Mental Health, Bethesda, Maryland/USA, and the Psychiatric Department of the University of Bonn, Germany; in neurology at the Neurological Department of the University of Heidelberg in Mannheim; and psychotherapeutic and psychoanalytic training at the Ausbildungsinstitut für Psychotherapie und Psychoanalyse in Heidelberg/Mannheim, Germany.
Dr. Kasper published 945 in ISI (http://portal.isiknowledge.com) listed publications (Citation Index: 13.042, Hirsch-Index: 61) and more than 200 book chapters, in various areas of psychiatry. He concentrates on the biological bases of mental disorders and their possible treatment approaches. Furthermore, he has conducted studies in psychopathological as well as clinical areas. Dr Kasper is a frequent national and international speaker and continues to be actively involved in research programmes studying depression, anxiety, psychosis, and dementia.
Dr. Kasper serves/served on the executive committees and advisory boards of several national and international societies, such as the European College of Neuropsychopharmacology (ECNP) and the European Psychiatric Association (EPA). He has been elected to the Executive Committee of the International College of Neuropsychopharmacology (CINP) for the period of 2012 to 2016. Moreover Dr. Kasper is Chair of the World Psychiatric Association (WPA) Section of Pharmacopsychiatry. He is Founding President of the Austrian Society of Drug Safety in Psychiatry (ÖAMSP) and of the Austrian Society of Neuropsychopharmacology and Biological Psychiatry (ÖGPB). Furthermore, he is an Honorary Member of the Czech and Romanian Societies of Neuropsychopharmacology, the Hungarian Psychiatric Association and a Fellow of the Royal College of Psychiatrists, UK, as well as of the Ukrainian Association of Psychiatry. Furthermore, he has been appointed Honorary Professor at the University of Hong Kong, China in 2005. In 1997, he was President of the 10th ECNP Congress, was Chairman of the Local Organizing Committee of the WPA Thematic Conference in 2004 and Co-Chair of the Local Organizing Committee of the WFSBP Congress 2005 and in 2007 Local Advisor for the ECNP congress in Vienna. In 2009, he was President of the WFSBP Congress in Paris. From 2005 to 2009 Dr. Kasper was President of the World Federation of Societies of Biological Psychiatry (WFSBP) and has been appointed as honorary president of the WFSBP in 2013.
Dr. Kasper serves on the editorial boards of numerous learned journals (total 53), including Journal of Clinical Psychiatry, CNS Spectrums, Journal of Affective Disorders, Pharmacopsychiatry, European Archives of Psychiatry and Neuroscience. He is Chief-Editor of the World Journal of Biological Psychiatry and the International Journal of Psychiatry in Clinical Practice, and Field Editor of the International Journal of Neuropsychopharmacology.
As a result of his research expertise he is the recipient of numerous national and international scientific and public awards and prizes and has recently been acknowledged with the Commander’s Cross II-nd class of the Republic of Austria.
Brian Dean, Australia
Brian Dean began his undergraduate training at the University of Sunderland where he was awarded a Higher National Diploma in Applied Biology specialising in Pharmacology and Parasitology. Further study at London South Bank University lead to admission to the Institute of Biology as a Licentiate (by examination) specialising in biochemistry. Subsequently, Brian completed his Masters of Science and Doctoral Degree at the University of Melbourne in Australia.
Brian Dean has been a member of CINP since 1992. He was a Councillor of the CINP from 2006 to 2010 and a member of the Pacific – Asia Regional Committee since 2002. Between 2008 and 2010 Brian was a member of the Financial Governance Committee and the Education Committee of the CINP and was involved in developing the Education Stream of the CINP Congress in Hong Kong.
Brian Dean is currently and NHMRC Senior Research Fellow (Level B) and Head of the Rebecca L. Cooper Research Laboratories at the Mental Health Research Institute, Melbourne, Australia and holds an honorary position as Professor of Psychiatry at the University of Melbourne. He has now published more than over 170 papers on the neuropsychopharmacology of psychotropic drugs and the pathophysiology of schizophrenia, bipolar disorder and major depressive disorders. This research strategy is based on the posits that improved treatments for psychiatric disorders requires a better understanding of the mechanisms of action of existing drugs and a much improved understanding of the causes of psychiatric disorders.
Some of the major research discoveries made by Brian Dean’s Laboratory are that there is:
• Increase levels of cannabis 1 receptors in the cortex of subjects with schizophrenia
• Decrease cortical serotonin2A receptors in schizophrenia
• A sub-group of subjects with schizophrenia that can be separated into a discrete population based on a loss of 75% of their cortical muscarinic M1 receptors
• Increased levels of transmembrane TNFα in the cortex of subjects with mood disorders
• Treating rats with clozapine causes regionally-selective decreases in cannabis 1 receptors
• A reactive metabolite of clozapine causes decreased cell survival in a human bone marrow stromal cell line
Brian Dean is a Fellow of the Collegium Internationale Neuro-Psychopharmacologium and the Society of Biology (UK). He is currently a member of the Board of the Rebecca L. Cooper Medical Research Foundation and the Finance Committee of the Schizophrenia International Research Society. At the national level, Brian Dean is President of the Melbourne Chapter of the Society for Neuroscience and a member of the Steering Committee for Biological Psychiatry Australia.
Prof. Elias Eriksson, Sweden